Table 3 Outcomes in pre-matched and propensity-matched groups
Pre-matched cohort | Matched cohort | |||||
|---|---|---|---|---|---|---|
n-TPE (n = 109) | TPE (n = 218) | p | n-TPE (n = 78) | TPE (n = 116) | p | |
CTSI changes in 14 days | ||||||
n = 25 | n = 57 | n = 22 | n = 47 | |||
Improved | 13 (52%) | 20 (35.09%) | 0.221 | 9 (40.90%) | 15 (31.91%) | 0.589 |
Deteriorated | 11 (44%) | 30 (52.63%) | 0.632 | 9 (40.90%) | 26 (55.32%) | 0.309 |
Unchanged | 1 (0.04%) | 7 (12.28%) | 0.424 | 4 (18.18%) | 6 (12.77%) | 0.715 |
Early recurrence (in 3 months) | ||||||
All type cases | 8 n = 84 (9.52%) | 4 n = 161 (2.48%) | 0.025 | 6 n = 67 (8.96%) | 2 n = 109 (1.83%) | 0.055 |
Only SAP included | 6 n = 36 (16.66%) | 2 n = 91 (2.19%) | 0.007 | 4 n = 27 (14.81%) | 0 n = 44 (0.00%) | 0.026 |
Treatment complications | ||||||
Venous embolism | 0 | 6 | 0.083 | |||
Local complications | ||||||
15 (13.76%) | 43 (19.72%) | 0.117 | 12 (15.38%) | 24 (20.69%) | 0.452 | |
Median length of stay, days (IQR) | ||||||
All type cases | 8 (6, 10) | 11 (6, 15) | 0.000 | 8 (6, 11) | 11 (8, 15) | 0.000 |
SAP | 8.5 (6.25, 11) | 13 (9, 18) | 0.000 | 9 (7, 11) | 13 (9.25, 18) | 0.001 |
Mortality | ||||||
1 (1.28%) | 2 (1.72%) | 1 | ||||